Advertisement

Picture EBD Group BIO-Europe 2018 Copenhagen Denmark Partnerships 600x60px
Document › Details

Affimed N.V.. (11/18/14). "Press Release: Affimed Reports Financial Results for Third Quarter 2014. Use of IPO Proceeds to Enhance Clinical Programs". Heidelberg.

Organisations Organisation Affimed N.V. (Nasdaq: AFMD)
  Group Affimed (Group)
  Organisation 2 Nasdaq Global Market
  Group Nasdaq OMX (Group)
Products Product AFM13 (Affimed)
  Product 2 AFM11 (Affimed)
  Index term 2 Affimed–SEVERAL: investment, 201405–201409 IPO $56m+$8.4m offering 8m+1.2m common shares $7/share at Nasdaq
Persons Person Hoess, Adi (Affimed 201109– CEO before CCO before Jenowis + Jerini 2003– + Carl Zeiss AG + MorphoSys AG)
  Person 2 Modig, Berndt (Pharvaris CEO before Prosensa 201003 CFO before Jerini 200310– CFO before Surplex AG)
     


   
Record changed: 2017-04-02

Advertisement

Picture Lipotype Lipidomics Drug Biomarker Discovery iito 600x60px

More documents for Affimed (Group)


To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Advertisement

Picture Berlin Partner HealthCapital RegMed Forum 2018 October 600x60px




» top